Nivolumab Improves Survival in Head and Neck Cancer
Nivolumab improved overall survival in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
AACR 2016
Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma
After 5 years of follow-up, 34% of patients with advanced melanoma who participated in a phase 1 clinical trial are still alive after receiving nivolumab treatment.
Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer
Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.
MammaPrint Test Reduces Use of Adjuvant Chemo Among Patients With Early-stage Breast Cancer
The MammaPrint genetic test can reduce the use of adjuvant chemotherapy following surgery among patients with early-stage breast cancer.
Early Negativization of BRAF V600 in cfDNA Linked to Excellent Prognosis in Melanoma
Patients with early negativization of BRAF V600 in tumor-derived circulating cell-free DNA (cfDNA) have excellent prognosis.
Circulating SAA, CXCL4 May Predict Osteosarcoma Outcome at Diagnosis
High serum amyloid A (SAA) and low CXC chemokine ligand 4 (CXCL4) at time of initial diagnosis are associated with poorer prognosis in osteosarcoma.
FGFR1 Overexpression Common in Adult Patients With Soft Tissue Sarcoma
Fibroblast growth factor receptor 1 (FGFR1) amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma.
Adding Bevacizumab to Chemoimmunotherapy Improves PFS in CLL
Adding bevacizumab to front-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab (PCR) may be safe and effective.
IL17F-rs9463772 Predicts Long-term Outcome in Rectal Cancer
Single nucleotide polymorphism (SNP) IL17F-rs9463772 represents a prognostic marker of long-term survival in locally advanced rectal cancer.
KRAS Mutation in cfDNA Linked to Response to Chemo in Pancreatic Cancer
KRAS mutation in cell-free DNA (cfDNA) may be associated with treatment response to gemcitabine plus cisplatin chemotherapy in pancreatic cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AACR 2016
Loading... 
Loading...